Gene · 554
Papers2,697
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,697
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Disappearance of Posterior Pituitary Hyperintensity in Arginine Vasopressin Resistance: A Case Report. | Turk Arch Pediatr | 2026 | 42826241 | PubTator, text mining | PubMed |
| Functional characterization of genetic variants associated with rare inherited renal disorders in the Sri Lankan population. | Mol Genet Genomics | 2026 | 42814169 | PubTator, text mining | PubMed |
| Methylation Mesa define functional regulatory elements for targeted gene activation. | Nat Commun | 2026 | 42786170 | PubTator, text mining | PubMed |
| Impact of fluconazole in vasopressin 2 receptor-related congenital arginine vasopressin resistance. | Kidney Int | 2026 | 42785711 | PubTator, text mining | PubMed |
| Large-scale organoid-derived cyst cultures as a drug discovery platform for polycystic kidney disease. | Kidney Int | 2026 | 42772449 | PubTator, text mining | PubMed |
| Tolvaptan in heart failure: Contemporary evidence and a framework for precision decongestion. | Heart Fail Rev | 2026 | 42714631 | PubTator, text mining | PubMed |
| Nephrogenic Syndrome of Inappropriate Antidiuresis: Case Report and Genetic Perspectives. | Nephrology (Carlton) | 2026 | 42685775 | PubTator, text mining | PubMed |
| Universal pipeline for high-resolution GPCR structure determination. | Nat Struct Mol Biol | 2026 | 42665663 | PubTator, text mining | PubMed |
| SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials. | Int Urol Nephrol | 2026 | 42584781 | PubTator, text mining | PubMed |
| X-Linked Nephrogenic Diabetes Insipidus Associated with the AVPR2 c.964C>T (p.Pro322Ser) Variant: A Family Case Series. | J Clin Med | 2026 | 42513428 | PubTator, text mining | PubMed |
| Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma. | Front Med (Lausanne) | 2026 | 42494441 | PubTator, text mining | PubMed |
| Kinome-wide CRISPR/Cas9-knockout screening reveals critical protein kinases in vasopressin V2-receptor signaling. | bioRxiv | 2026 | 42465376 | PubTator, text mining | PubMed |
| Clean intermittent catheterization reverses hydronephrosis in a child with congenital nephrogenic diabetes insipidus: a case report. | Can J Urol | 2026 | 42415594 | PubTator, text mining | PubMed |
| When X Does Not Mark the Spot: Autosomal Dominant and Recessive Forms of Renal Hypophosphatemic Rickets and Osteomalacia. | Curr Osteoporos Rep | 2026 | 42412262 | PubTator, text mining | PubMed |
| GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing. | Transl Res | 2026 | 42398811 | PubTator, text mining | PubMed |
| Vasopressin type-2 receptor mRNA expressions in endolymphatic sac and temporal bone cT findings in Meniere's disease. | Acta Otolaryngol | 2026 | 42396990 | PubTator, text mining | PubMed |
| The Gut Microbiome May Play a Role in the Pathogenesis of Meniere's Disease. | J Int Adv Otol | 2026 | 42345435 | PubTator, text mining | PubMed |
| Infant Nephrogenic Diabetes Insipidus: Challenges Leading to Delayed Management. | Case Rep Med | 2026 | 42344104 | PubTator, text mining | PubMed |
| Autoimmune small-vessel cerebral vasculitis with refractory SIADH: clinical recovery after V2-receptor antagonism (tolvaptan). | BMJ Case Rep | 2026 | 42315243 | PubTator, text mining | PubMed |
| GLUT9b- and ABCG2-mediated collecting duct urate transport uncovers a vasopressin-independent mechanism of renal water reabsorption. | J Clin Invest | 2026 | 42298327 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/554/papers